- Home
- OESX vs PRTG Comparison
OESX vs PRTG Comparison
Compare OESX & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OESX
- PRTG
- Stock Information
- Founded
- OESX 1996
- PRTG 1973
- Country
- OESX United States
- PRTG British Virgin Islands
- Employees
- OESX N/A
- PRTG N/A
- Industry
- OESX Building Products
- PRTG Oil & Gas Production
- Sector
- OESX Consumer Discretionary
- PRTG Energy
- Exchange
- OESX Nasdaq
- PRTG Nasdaq
- Market Cap
- OESX 19.1M
- PRTG 17.7M
- IPO Year
- OESX 2007
- PRTG N/A
- Fundamental
- Price
- OESX $0.63
- PRTG $5.69
- Analyst Decision
- OESX Strong Buy
- PRTG
- Analyst Count
- OESX 1
- PRTG 0
- Target Price
- OESX $3.00
- PRTG N/A
- AVG Volume (30 Days)
- OESX 135.2K
- PRTG 233.8K
- Earning Date
- OESX 06-26-2025
- PRTG 08-14-2025
- Dividend Yield
- OESX N/A
- PRTG N/A
- EPS Growth
- OESX N/A
- PRTG N/A
- EPS
- OESX N/A
- PRTG N/A
- Revenue
- OESX $85,262,000.00
- PRTG N/A
- Revenue This Year
- OESX N/A
- PRTG N/A
- Revenue Next Year
- OESX $17.14
- PRTG N/A
- P/E Ratio
- OESX N/A
- PRTG N/A
- Revenue Growth
- OESX N/A
- PRTG N/A
- 52 Week Low
- OESX $0.56
- PRTG $2.10
- 52 Week High
- OESX $1.29
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- OESX 60.27
- PRTG 39.99
- Support Level
- OESX $0.63
- PRTG $5.24
- Resistance Level
- OESX $0.61
- PRTG $6.84
- Average True Range (ATR)
- OESX 0.03
- PRTG 0.76
- MACD
- OESX 0.01
- PRTG -0.09
- Stochastic Oscillator
- OESX 92.31
- PRTG 18.10
About OESX Orion Energy Systems Inc.
Orion Energy Systems Inc is a developer, manufacturer, and seller of lighting and energy management systems. The company segments include Orion Lighting Segment, Orion Maintenance Segment and Orion Electric Vehicle Charging Segment. It derives maximum revenue from Lighting Segment.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.